Accent Therapeutics Completes $75M Series C Financing

Lexington, MA, January 23, 2024 (PRNewswire) -- Accent Therapeutics has successfully concluded its Series C financing, securing a total of $75 million. The funding round was spearheaded by Mirae Asset Capital Life Science, with active participation from additional new investors such as Mirae Asset Capital, Mirae Asset Venture Investment, Bristol Myers Squibb, and Johnson & Johnson Innovation – JJDC, Inc. It also enjoyed continued support from existing investors, including The Column Group, Atlas Venture, Droia Ventures, GV, EcoR1 Capital, AbbVie Ventures, The Mark Foundation for Cancer Research, Timefolio Capital (formerly known as NS Investment), and others. Accent Therapeutics is a pioneering biopharmaceutical company in the development of a novel class of small molecule precision cancer therapies.

Read full article here.